Dr. Ryan Lynch, MD
Claim this profileFred Hutch/University of Washington Cancer Consortium
Studies Non-Hodgkin's Lymphoma
Studies Hodgkin's Lymphoma
9 reported clinical trials
23 drugs studied
Area of expertise
1Non-Hodgkin's Lymphoma
2Hodgkin's Lymphoma
Stage I
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Ryan Lynch, MD is currently running
Polatuzumab Vedotin + Chemotherapy
for Large B-Cell Lymphoma
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Glofitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in combination chemotherapy with or without glofitamab may help treat patients with aggressive large B-cell lymphoma.
Recruiting1 award Phase 1
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting1 award Phase 25 criteria
More about Ryan Lynch, MD
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ryan Lynch, MD has experience with
- Dacarbazine
- Doxorubicin
- Rituximab
- Nivolumab
- Vinblastine
- Polatuzumab Vedotin
Breakdown of trials Ryan Lynch, MD has run
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Mixed-Cell Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ryan Lynch, MD specialize in?
Ryan Lynch, MD focuses on Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Ryan Lynch, MD currently recruiting for clinical trials?
Yes, Ryan Lynch, MD is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Ryan Lynch, MD has studied deeply?
Yes, Ryan Lynch, MD has studied treatments such as Dacarbazine, Doxorubicin, Rituximab.
What is the best way to schedule an appointment with Ryan Lynch, MD?
Apply for one of the trials that Ryan Lynch, MD is conducting.
What is the office address of Ryan Lynch, MD?
The office of Ryan Lynch, MD is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.